Navigation Links
ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohn's Disease at the Digestive Disease Week (DDW) 2010 Conference
Date:5/4/2010

NEW ORLEANS, May 4 /PRNewswire/ -- ChemoCentryx, Inc., today announced that it reported positive data with Traficet-EN™ (CCX282-B) in the Maintenance period of PROTECT-1 (Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial-1).   Traficet-EN maintained a clinical remission rate (Crohn's Disease Activity Index (CDAI) less than 150) of approximately 50% in Crohn's patients over the course of 36 weeks, whereas in the placebo group remission decreased progressively from 50% to 31%. The difference in remission rate between the two groups was statistically significant (p=0.01) at week 36. Also, at week 36, a statistically significant percentage of patients receiving Traficet-EN versus placebo were in corticosteroid-free remission and had normalized C-reactive protein (CRP) levels.  Traficet-EN continued to be safe and well-tolerated for the entire course of the PROTECT-1 study (aggregate dosing up to one year). These data were presented today in an oral session at the Digestive Disease Week (DDW) conference in New Orleans by Satish Keshav, M.D., Ph.D., Department of Gastroenterology, John Radcliffe Hospital, Oxford University.

The results from the Maintenance period of PROTECT-1 reported here confirmed and expanded the efficacy of Traficet-EN that was observed in the preceding Induction period of the study, which was reported in 2009.

"Treatment for inflammatory diseases of the bowel including Crohn's has been woefully insufficient for far too long for such a devastating disease," said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx.  "We believe Traficet-EN represents a paradigm shift in terms of safety and efficacy for these patients, of
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
6. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. Spherix Reports Second Quarter Earnings
10. Tapestry Reports Second Quarter 2007 Results
11. Callisto Reports on Second-Quarter 2007 Milestones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... LOUIS , July 11, 2014 /PRNewswire/ ... device company, announced today the positive, cost-effective ... its innovative SPiNPerc™ procedure. The SPiNPerc endobronchial ... of a percutaneous approach to biopsy when ... Hospitals, patients and physicians experience positive financial ...
(Date:7/10/2014)... NEWS, Virginia , 11. Juli ... Hersteller von Kameras für die molekulare ... (MBI/BSGI), hat heute die CE-Zulassung für ... dem CE-Zeichen kann Dilon das Produkt ... Vertriebsbereich auf den Großteil der europäischen ...
(Date:7/10/2014)... , July 10, 2014  RESMED INC. (NYSE: ... fourth quarter and fiscal year ended June 30, 2014 results ... Exchange market close. A press release with ResMed,s results will ... company will host a webcast to discuss operating results and ... begin at 1:30 p.m. US Pacific Time and the live ...
Breaking Medicine Technology:Veran Medical Publishes Lung Cancer Patient Management Study 2Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... Group, an international generic pharmaceuticals company, today announced ... Extended-Release Tablets, 2mg, 4mg, 6mg, 8mg and 12mg, ... believes this is the first generic Requip® XL ... has commenced.   Requip® XL, 2mg, 4mg, ...
... Mass. and TORONTO, May 18, 2012 Generex ... members have joined the Scientific Advisory Board (SAB) ... the company,s AE37 breast cancer vaccine.  The following ... N. Hortobagyi, MD, FACP (University of Texas MD ...
Cached Medicine Technology:Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets) 2Generex Augments Antigen Express Scientific Advisory Board 2Generex Augments Antigen Express Scientific Advisory Board 3Generex Augments Antigen Express Scientific Advisory Board 4
(Date:7/12/2014)... 12, 2014 Floor-grade instrument ... 4.1 out of 5. This above-average score represents ... underpinning buyer negotiation power over the three years ... Son, “during the period, surging demand for healthcare ... with new product development, have placed upward pressure ...
(Date:7/12/2014)... The largest pure occupational medicine company ... announce that it will be opening its fifth Georgia ... join four Atlanta-based Nova Medical Centers’ locations. The ... Bridge Road, and will be open from 8:30 a.m. ... Nova’s treatment philosophy of rapid return-to-work and decreased treatment ...
(Date:7/11/2014)... Recently, MagicQuinceaneraDresses.com, the popular online supplier of special ... Quinceanera dresses . The company’s new items are ... without paying a large amount of money. They are ... , The company’s online shop has become a one ... outfits. In addition to exquisite Quinceanera dresses, it also ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 The American ... America’s 55 poison centers are commending Senator Bill Nelson ... Prevention Act of 2014 on July 10, 2014. Along ... Consumer Products Safety Commission (CPSC) to enact rules requiring ... consumers. , Senate co-sponsors of the bill ...
(Date:7/11/2014)... reports that tickets to the Argentina vs. Germany World ... Brazil and Netherlands are in high demand. The ... at Estadio Nacional de Brasilia Mane Garrincha Brasila, Federal District. ... 13th at Estadio Jornalista Mario Filho - Estadio do Maracana, ... are guaranteed to be authentic and are covered by Ticket ...
Breaking Medicine News(10 mins):Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 4Health News:Nova Medical Centers To Open New Facility in Augusta, Georgia 2Health News:Cheap Quinceanera Dresses Now Available At MagicQuinceaneraDresses.com 2Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 2Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 3Health News:Argentina vs. Germany World Cup Finals Tickets & Brazil vs. Netherlands 3rd Place World Cup Tickets Are in Huge Demand 2
... Afghanistan and Nigeria is a polio-endemic country, according to ... the indigenous polio transmission, according to the report. // ... the virus has also been announced. ,The ... phase with the next-generation vaccines targeting the two surviving ...
... Kong from buying poultry from southern China. Chicken happens to be ... One seller at a market close to the border said Hong ... to make it easier to get them through the customs. ... of three from a village in the Shataukok border area were ...
... India for the sake of low priced cosmetic surgery. ... rhinoplasty, and breast improvements are very expensive. // Over ... every year. ,Recent figures released by ... breast enlargement topped the list of cosmetic operations performed ...
... affected as a result of snoring, according to research results ... Center // in Illinois. Most women are negatively affected by ... to divorces, according to the research. As many as 10 ... tense relationship develops between the couple when one of them ...
... on the verge of path breaking news that suggests ... // Reduced vitamin D levels in the mother ... onset of this disorder, according to the research report, ... long frozen Danish samples hold the clues that will help ...
... been raised against a Food Standards Agency advertisement, ... appropriate evidence. // An investigation was ordered following ... a salt-challenge had lowered their hypertension by consuming ... that examined the case stated that there was ...
Cached Medicine News:Health News:More People Come To India For Cosmetic Surgery 2Health News:Sunny Side Up - Vitamin-D deficiency linked to Schizophrenia 2Health News:Government Advertisement Faces Criticism For Wrong Salt Claim 2
... the most useful features is the PupilFit ... mathematical analysis of the pupil images, producing ... instantaneously. The fitted circle is shown as ... proof that the measurement ismeaningful, and not ...
Dual-sided, Interhemispheric Grid Electrode with 16 Contact Leads; Cortical Grid Electrode with 16 Contact Leads; Pediatric Grid Electrode with Flex Connector, 0.5 cm spacing...
Ad-Techs Epidural Peg Electrodes feature a silicone-insulated titanium contact. To accommodate varying skull thicknesses, the post lengths range in length from 4 to 16 mm. The connecting lead wires e...
...
Medicine Products: